Perspectives

Reactive astrocytes as therapeutic targets in neurodegenerative disease

Phase IIa exploratory trial of T3D-959 in mild-moderate Alzheimer’s disease

Preliminary results from the Phase II PIONEER trial of T3D-959 in mild-moderate Alzheimer’s disease

The metabolic hypothesis of Alzheimer’s disease

Is amyloid lowering still a valid approach in Alzheimer’s disease?

Future research directions for neuropsychiatric symptoms in Alzheimer’s disease

Ethical considerations when investigating the causes of mild cognitive impairment

A new definition of brain resilience

Brain health should the top priority worldwide

The importance of joint prevention programs for dementia, stroke and heart disease

Understanding Alzheimer’s disease in Down syndrome

The validity of the amyloid cascade hypothesis of Alzheimer’s disease

Should findings from monogenic dementias inform sporadic disease research?

Including people with Down syndrome in Alzheimer’s disease research

Efforts to understand the pathological mechanisms of neurodegenerative processes

Are viruses a major cause of amyloid deposition in Alzheimer’s disease?